A method for isolating neutral polysaccharides with SARS-CoV-2 S protein binding activity from ephedra polysaccharides

By employing a combination of CTAB selective precipitation and salting-out and dialysis purification techniques, we have achieved efficient separation and large-scale application of ephedra polysaccharides. We have identified neutral polysaccharides as the core active component in ephedra polysaccharides that binds to the SARS-CoV-2 S protein. This approach solves the problems of cumbersome operation and low separation efficiency in existing ephedra polysaccharide separation methods and provides a material basis for anti-COVID-19 related fields.

CN122302113APending Publication Date: 2026-06-30赣江中药创新中心
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
赣江中药创新中心
Filing Date
2026-04-01
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing methods for separating ephedra polysaccharides are cumbersome and inefficient, making it difficult to achieve efficient separation and large-scale application of acidic and neutral polysaccharides. Furthermore, the core active components in ephedra polysaccharides that bind to the COVID-19 S protein have not been identified.

Method used

Selective precipitation with cetyltrimethylammonium bromide (CTAB) combined with salting and dialysis purification techniques was used to separate ephedrine polysaccharides by charge difference, obtaining neutral polysaccharide components with SARS-CoV-2 S protein binding activity. The specific binding activity of the polysaccharide to SARS-CoV-2 S protein was verified by biomembrane interference.

Benefits of technology

This study achieved efficient separation and large-scale application of ephedra polysaccharides, identified neutral polysaccharides as the core active component in ephedra polysaccharides that binds to the SARS-CoV-2 S protein, and provided a material basis for in-depth development in the field of anti-COVID-19.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention discloses a method for isolating neutral polysaccharides with SARS-CoV-2 S protein binding activity from ephedra polysaccharides, belonging to the field of natural product separation and purification technology. Targeting a mixed system of acidic and neutral polysaccharides in ephedra, this method utilizes the characteristic of hexadecyltrimethylammonium bromide forming an insoluble complex with acidic polysaccharides. Through steps such as complexation precipitation, salt dissociation, dialysis, and lyophilization, efficient separation of acidic and neutral ephedra polysaccharides is achieved. Biomembrane interference experiments verify that the neutral ephedra polysaccharides obtained after removing the acidic polysaccharides by this method have specific binding activity with the SARS-CoV-2 S protein, while the acidic polysaccharides do not exhibit this binding activity. This method is simple, highly efficient, and effectively obtains well-defined neutral and acidic polysaccharide components from ephedra, with the neutral polysaccharides being the core active component binding to the SARS-CoV-2 S protein.
Need to check novelty before this filing date? Find Prior Art